Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 268

Sort by

Sort Order Select

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Gang Lu, Christine Surka, Chin-Chun Lu, In Sock Jang, PhD, Kai Wang, PhD, Mark Rolfe, PhD

Blood (2019) 134 (Supplement_1): 405.

https://doi.org/10.1182/blood-2019-125492

Published: 2019

Journal Articles

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

Catherine Rondelli, Aiden Danoff, Hector Bergonia, Samantha Gillis, Julia Free, John D. Phillips, PhD, Yvette Y Yien, PhD

Blood (2019) 134 (Supplement_1): 427.

https://doi.org/10.1182/blood-2019-132039

Published: 2019

Journal Articles

Chaperone-Mediated Autophagy Ensures Hematopoietic Stem Cell Maintenance

Shuxian Dong, PhD, Britta Will, PhD, Ana Maria Cuervo, MD PhD

Blood (2019) 134 (Supplement_1): 272.

https://doi.org/10.1182/blood-2019-132230

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Jiliang Xia, PhD, Yanjuan He, MD, Bin Meng, Jingyu Zhang, Xuan Wu, Xiangling Feng, PhD, Chunmei Kuang, Jiaojiao Guo, Yinghong Zhu, Qian Lei, Yongjun Guan, Yi Shen, MD PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 4332.

https://doi.org/10.1182/blood-2019-126617

Published: 2019

Journal Articles

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Blood (2019) 134 (Supplement_1): 4224.

https://doi.org/10.1182/blood-2019-124458

Published: 2019

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Glia Maturation Factor-γ Regulates Autophagy in Murine Macrophages

Wulin Aerbajinai, MD PhD, Jianqiong Zhu, MD, Chutima Kumkhaek, PhD, Kyung Chin, Griffin Rodgers, MD

Blood (2019) 134 (Supplement_1): 2318.

https://doi.org/10.1182/blood-2019-130318

Published: 2019

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Tohru Fujiwara, MD PhD, Chie Suzuki, Tetsuro Ochi, Koya Ono, MD, Kei Saito, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Shinichi Fujimaki, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 2232.

https://doi.org/10.1182/blood-2019-123918

Published: 2019

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Rebecca Valentin, MD, Marisa O. Peluso, MS, Timothy Z. Lehmberg, BA, Ammar Adam, DVM, Li Zhang, MA, Caroline M. Armet, BS, Jennifer L. Guerriero, PhD, Benjamin H. Lee, MD PhD, Vito J. Palombella, PhD, Pamela M. Holland, PhD, Alison M. Paterson, PhD, Matthew S. Davids, MD

Blood (2018) 132 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2018-99-110181

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD

Blood (2018) 132 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2018-99-118456

Published: 2018

Journal Articles

The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma

Kenta Mukaihara, MD PhD, Ka Tat Siu, PhD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Cherrie Huang, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2018-99-114922

Published: 2018

Journal Articles

The Inhibition of Platelets Restore Anti-Tumor Immune Response to Ovarian Cancer and Its Therapeutic Implication

Min Soon Cho, PhD, Omayra Gonzalez-Pagan, MD PhD, Karem Court Pinto, PhD, Anil Sood, MD, Vahid Afshar-Kharghan, MD

Blood (2018) 132 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2018-99-116530

Published: 2018

Journal Articles

Investigating the Role of C/Ebpδ-Deficiency in Radiation-Induced Bone Marrow Failure

Debajyoti Majumdar, BPharm, MPharm, Eric Pietras, PhD, Jason Stumhofer, PhD, Snehalata A Pawar, PhD

Blood (2018) 132 (Supplement 1): 5103.

https://doi.org/10.1182/blood-2018-99-119671

Published: 2018

NARROW

A complementary new drug for PNH

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

Chaperone-Mediated Autophagy Ensures Hematopoietic Stem Cell Maintenance

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Glia Maturation Factor-γ Regulates Autophagy in Murine Macrophages

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma

The Inhibition of Platelets Restore Anti-Tumor Immune Response to Ovarian Cancer and Its Therapeutic Implication

Investigating the Role of C/Ebpδ-Deficiency in Radiation-Induced Bone Marrow Failure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only